Skip to content

In crisis? Call or text 988. In an emergency, call 911.

Brixadi treatment

We understand the complexity of addiction.

JADE remains a pioneer in opioid addiction treatment, now offering the long-acting buprenorphine injectable, Brixadi.

What is Brixadi?

Extended relief, weekly or monthly.

Brixadi (buprenorphine) extended-release subcutaneous injection treats moderate to severe opioid use disorder (OUD) in patients who have started treatment with a single dose of a transmucosal buprenorphine product (like Suboxone) or who are already being treated with buprenorphine.

Brixadi comes in weekly or monthly formulations for subcutaneous injection into the buttock, thigh, abdomen or upper arm. It helps break the cycle of cravings and withdrawal as a key part of a comprehensive treatment program.

Key components of Brixadi

  • Long-acting subcutaneous buprenorphine injection
  • Works on the mu-opioid receptor as a partial agonist
  • Approved for moderate to severe opioid use disorder
  • Same active ingredient as Sublocade (buprenorphine monotherapy)
  • Multiple strengths and dosages
  • Two formulations: weekly or monthly
  • Given in the thigh, abdomen or buttocks; upper arm only after dose #4 (steady state)

Take the first step

Your recovery partner.

Discover the power of Brixadi and the support of a caring team who will stand by your side on the journey to a healthier life.